It looks like an Oct. 3 go for Pfizer Inc. and its partner Celltrion Inc. to launch their biosimilar Inflectra (infliximab-dyyb) after reports surfaced the first batch of the drug had been shipped and new court documents revealed the companies had entered into a new agreement with Johnson & Johnson unit Janssen Biotech Inc. to clear the way for US marketing.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?